Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily)
administered orally for a period of 16 weeks in reducing risky drinking among currently
drinking subjects with alcohol use disorder who have selected genotypes at the serotonin
transporter and receptor genes. The secondary objective is to assess the safety and
tolerability of ondansetron in subjects with alcohol use disorder who have selected genotypes
at the serotonin transporter and receptor genes.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore